Elliot Stieglitz

This paper identifies RNR inhibition as a strategy to overcome FLT3 inhibitor resistance in FLT3ITD+ AML by reversing resistance mechanisms and enhancing therapeutic efficacy.

This study investigates the Daple-FLT3 gene fusion, showing its constitutive kinase activity and pericentrosomal localization, with the coiled-coil domain required for maximal activation.

This study evaluates RMC-7977, a RAS(ON) inhibitor, showing efficacy against RAS-driven resistance in AML and potential for combination therapies.

Structure-optimized CD27-based CAR-T cells targeting CD70 show >80-fold improved expansion in vivo and offer a potential therapy for high-risk multiple myeloma patients.

This study validates the palmitoylation cycle as a therapeutic target in NRAS-mutant cancers by showing that inhibiting ABHD17 reduces tumor growth and synergizes with MEK inhibitors.